Design Therapeutics, Inc. financial data

Symbol
DSGN on Nasdaq
Location
Carlsbad, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 09 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2151% % -39%
Debt-to-equity 5.3% % 48%
Return On Equity -33% % -69%
Return On Assets -31% % -66%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61,672,279 shares 8.6%
Common Stock, Shares, Outstanding 60,398,051 shares 6.4%
Entity Public Float $114,342,718 USD 1.6%
Common Stock, Value, Issued $6,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 57,330,192 shares 1.3%
Weighted Average Number of Shares Outstanding, Diluted 57,330,192 shares 1.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD
Research and Development Expense $59,129,000 USD 33%
General and Administrative Expense $20,338,000 USD 13%
Operating Income (Loss) $79,467,000 USD -27%
Net Income (Loss) Attributable to Parent $69,792,000 USD -41%
Earnings Per Share, Basic -1.22 USD/shares -39%
Earnings Per Share, Diluted -1.22 USD/shares -39%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $16,856,000 USD -25%
Marketable Securities, Current $202,989,000 USD -8.9%
Cash, Cash Equivalents, and Short-term Investments $219,800,000 USD -10%
Assets, Current $223,784,000 USD -9.8%
Property, Plant and Equipment, Net $981,000 USD -30%
Operating Lease, Right-of-Use Asset $1,438,000 USD -35%
Assets $226,203,000 USD -10%
Accounts Payable, Current $2,312,000 USD 5.8%
Employee-related Liabilities, Current $4,631,000 USD 30%
Accrued Liabilities, Current $10,743,000 USD 71%
Liabilities, Current $13,055,000 USD 54%
Operating Lease, Liability, Noncurrent $645,000 USD -58%
Liabilities $13,700,000 USD 37%
Accumulated Other Comprehensive Income (Loss), Net of Tax $403,000 USD -15%
Retained Earnings (Accumulated Deficit) $297,006,000 USD -31%
Stockholders' Equity Attributable to Parent $212,503,000 USD -12%
Liabilities and Equity $226,203,000 USD -10%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $16,789,000 USD -35%
Net Cash Provided by (Used in) Financing Activities $23,000 USD 15%
Net Cash Provided by (Used in) Investing Activities $7,870,000 USD -62%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 60,398,051 shares 6.4%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $8,896,000 USD -209%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $16,856,000 USD -25%
Deferred Tax Assets, Valuation Allowance $67,327,000 USD 27%
Deferred Tax Assets, Gross $67,873,000 USD 26%
Operating Lease, Liability $1,535,000 USD -34%
Depreciation $159,000 USD 11%
Payments to Acquire Property, Plant, and Equipment $72,000 USD -63%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $69,864,000 USD -42%
Lessee, Operating Lease, Liability, to be Paid $1,636,000 USD -37%
Property, Plant and Equipment, Gross $3,245,000 USD 5.9%
Operating Lease, Liability, Current $890,000 USD 11%
Lessee, Operating Lease, Liability, to be Paid, Year Two $663,000 USD -32%
Lessee, Operating Lease, Liability, to be Paid, Year One $973,000 USD 3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $101,000 USD -59%
Deferred Tax Assets, Operating Loss Carryforwards $31,412,000 USD 66%
Unrecognized Tax Benefits $2,812,000 USD 23%
Deferred Tax Assets, Net of Valuation Allowance $546,000 USD -35%
Share-based Payment Arrangement, Expense $14,549,000 USD 11%